Market News / Story
Cadrenal Therapeutics launches formal strategic review, retains Tungsten Advisors to maximize asset value
·
Cadrenal Therapeutics has initiated a formal strategic process to evaluate opportunities to maximize value of the company and its asset portfolio. Key Highlights: Board authorized a formal strategic review to evaluate licensing, asset sales, partnerships, portfolio transactions, or business combinations. Company retained Tungsten Advisors as exclusive strategic financial advisor to lead the process. Pipeline includes CAD-1005 (Phase 3 pathway aligned with FDA),…